Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

This study is testing SIRPant-M, an experimental drug that blocks a "don't eat me" signal on cancer cells (CD47), to help the immune system recognize and destroy cancer in people with relapsed or treatment-resistant non-Hodgkin's lymphoma (NHL) — a type of blood cancer affecting lymph nodes. **You may be eligible if...** - You are 18 or older with confirmed non-Hodgkin's lymphoma - Your cancer has come back or stopped responding to treatment - You have received at least 2 prior treatment regimens - You are not eligible for or have exhausted other curative-intent therapies - Your performance status and organ function are adequate for further treatment **You may NOT be eligible if...** - You have not received at least 2 prior lines of therapy - You have active autoimmune conditions requiring treatment - You have untreated brain involvement by lymphoma - You have serious anemia or other blood count problems that would be worsened by the drug's mechanism - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.